Two Sigma Investments LP boosted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 209.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 389,428 shares of the biotechnology company's stock after purchasing an additional 263,495 shares during the period. Two Sigma Investments LP owned about 0.79% of REGENXBIO worth $3,010,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS bought a new position in REGENXBIO during the 4th quarter worth about $54,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of REGENXBIO during the 4th quarter worth about $79,000. Laurion Capital Management LP acquired a new position in shares of REGENXBIO during the 4th quarter worth about $79,000. EntryPoint Capital LLC acquired a new position in shares of REGENXBIO during the 4th quarter worth about $97,000. Finally, Teacher Retirement System of Texas boosted its stake in shares of REGENXBIO by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock worth $97,000 after buying an additional 2,088 shares during the last quarter. Institutional investors own 88.08% of the company's stock.
REGENXBIO Stock Performance
NASDAQ:RGNX traded down $0.05 during mid-day trading on Wednesday, hitting $10.08. The stock had a trading volume of 690,256 shares, compared to its average volume of 904,943. REGENXBIO Inc. has a twelve month low of $5.04 and a twelve month high of $15.36. The stock has a market cap of $505.61 million, a price-to-earnings ratio of -2.00 and a beta of 1.11. The company's 50 day simple moving average is $8.01 and its 200 day simple moving average is $7.95.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.41 by ($0.29). The company had revenue of $89.01 million for the quarter, compared to analyst estimates of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. As a group, equities analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities analysts have recently commented on the stock. HC Wainwright reduced their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, March 17th. Raymond James assumed coverage on shares of REGENXBIO in a research note on Friday, February 7th. They set an "outperform" rating and a $27.00 price objective for the company. Chardan Capital restated a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Thursday, March 20th. Morgan Stanley raised their target price on shares of REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, March 14th. Finally, Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research note on Tuesday, March 18th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $31.63.
View Our Latest Stock Analysis on REGENXBIO
Insiders Place Their Bets
In other REGENXBIO news, Director Kenneth T. Mills sold 20,602 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $7.91, for a total transaction of $162,961.82. Following the completion of the sale, the director now directly owns 475,103 shares in the company, valued at $3,758,064.73. This trade represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 12.79% of the company's stock.
About REGENXBIO
(
Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Featured Articles
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
